[
  {
    "ts": "2025-11-18T06:16:51+00:00",
    "headline": "Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition",
    "summary": "Deal adds new prostate cancer candidate and supports J&J's long-term oncology strategy.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-expands-oncology-pipeline-061651954.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "4e3f32bc-fbb1-374b-b5f9-bb5c1ae32e68",
      "content": {
        "id": "4e3f32bc-fbb1-374b-b5f9-bb5c1ae32e68",
        "contentType": "STORY",
        "title": "Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition",
        "description": "",
        "summary": "Deal adds new prostate cancer candidate and supports J&J's long-term oncology strategy.",
        "pubDate": "2025-11-18T06:16:51Z",
        "displayTime": "2025-11-18T06:16:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/a631149e008fe04bcad182a629a22c2e",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nQahFoVt6_qKzx8G6FoELg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a631149e008fe04bcad182a629a22c2e.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yScmCasUkPZyvdIPPU4j.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a631149e008fe04bcad182a629a22c2e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-expands-oncology-pipeline-061651954.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-expands-oncology-pipeline-061651954.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T10:13:07+00:00",
    "headline": "Johnson & Johnson to acquire Halda Therapeutics for $3.05bn",
    "summary": "The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology portfolio.",
    "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-halda-therapeutics-3-05bn/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "8a01d1ca-5f52-3f19-8662-2185fff4ad1d",
      "content": {
        "id": "8a01d1ca-5f52-3f19-8662-2185fff4ad1d",
        "contentType": "STORY",
        "title": "Johnson & Johnson to acquire Halda Therapeutics for $3.05bn",
        "description": "",
        "summary": "The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology portfolio.",
        "pubDate": "2025-11-18T10:13:07Z",
        "displayTime": "2025-11-18T10:13:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/6edd94881ba09d9179e562cf8710320c",
          "originalWidth": 1440,
          "originalHeight": 811,
          "caption": "The acquisition brings Halda's lead candidate",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QuCpXe9bm4NWWNIQ_BW7eg--~B/aD04MTE7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/6edd94881ba09d9179e562cf8710320c.cf.webp",
              "width": 1440,
              "height": 811,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aJ03hgRyJ1AB0gK8mdqanQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/6edd94881ba09d9179e562cf8710320c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-halda-therapeutics-3-05bn/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-acquire-halda-therapeutics-101307944.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T09:27:00+00:00",
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum",
    "summary": "Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-092700816.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cb798202-0361-33be-862a-674ba250326d",
      "content": {
        "id": "cb798202-0361-33be-862a-674ba250326d",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum",
        "description": "",
        "summary": "Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.",
        "pubDate": "2025-11-18T09:27:00Z",
        "displayTime": "2025-11-18T09:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-092700816.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-092700816.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T14:37:00+00:00",
    "headline": "Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3",
    "summary": "ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.",
    "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c9e8ac52-48bc-3904-90f7-1459204d2244",
      "content": {
        "id": "c9e8ac52-48bc-3904-90f7-1459204d2244",
        "contentType": "STORY",
        "title": "Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3",
        "description": "",
        "summary": "ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.",
        "pubDate": "2025-11-18T14:37:00Z",
        "displayTime": "2025-11-18T14:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T16:03:00+00:00",
    "headline": "J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B",
    "summary": "J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.",
    "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3c349984-2127-394c-af6e-5b9be1a63904",
      "content": {
        "id": "3c349984-2127-394c-af6e-5b9be1a63904",
        "contentType": "STORY",
        "title": "J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B",
        "description": "",
        "summary": "J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.",
        "pubDate": "2025-11-18T16:03:00Z",
        "displayTime": "2025-11-18T16:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hD1XqSSX7ulRknhxAtE3Fg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WurdES47e08.qoEQbQD.wQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T11:30:00+00:00",
    "headline": "Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion",
    "summary": "J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.",
    "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-acquires-halda-therapeutics-for-3-1-billion/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "82ba981b-22f8-3d5f-a945-39f38962987e",
      "content": {
        "id": "82ba981b-22f8-3d5f-a945-39f38962987e",
        "contentType": "STORY",
        "title": "Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion",
        "description": "",
        "summary": "J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.",
        "pubDate": "2025-11-18T11:30:00Z",
        "displayTime": "2025-11-18T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/32a4da166e1918b112ac336e922dc839",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "The front of a Johnson and Johnson office with modern, angular architecture is shown against a blue sky.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HVRWQr02vklFH3cgY2t8rw--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/32a4da166e1918b112ac336e922dc839.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGgYJfHEl4OsuiSWzuOHzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/32a4da166e1918b112ac336e922dc839.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-acquires-halda-therapeutics-for-3-1-billion/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-buys-prostate-cancer-113000302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T22:09:50+00:00",
    "headline": "Why Johnson & Johnson (JNJ) Is Up 5.9% After Multiple FDA Approvals and Positive Drug Trial Results",
    "summary": "In November 2025, Johnson & Johnson announced several major product developments, including new FDA approvals for DARZALEX Faspro in high-risk smoldering multiple myeloma, CAPLYTA as an adjunctive treatment for major depressive disorder, and positive late-stage clinical results for TREMFYA in psoriatic arthritis. These achievements underline Johnson & Johnson's momentum in expanding its pharmaceutical portfolio with treatments targeting significant unmet medical needs across oncology,...",
    "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-5-220950364.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "53d27f36-2dc4-3282-b67d-535327761045",
      "content": {
        "id": "53d27f36-2dc4-3282-b67d-535327761045",
        "contentType": "STORY",
        "title": "Why Johnson & Johnson (JNJ) Is Up 5.9% After Multiple FDA Approvals and Positive Drug Trial Results",
        "description": "",
        "summary": "In November 2025, Johnson & Johnson announced several major product developments, including new FDA approvals for DARZALEX Faspro in high-risk smoldering multiple myeloma, CAPLYTA as an adjunctive treatment for major depressive disorder, and positive late-stage clinical results for TREMFYA in psoriatic arthritis. These achievements underline Johnson & Johnson's momentum in expanding its pharmaceutical portfolio with treatments targeting significant unmet medical needs across oncology,...",
        "pubDate": "2025-11-18T22:09:50Z",
        "displayTime": "2025-11-18T22:09:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-5-220950364.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-5-220950364.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:07:00+00:00",
    "headline": "3 Smart Defensive Stocks for an Uneasy Market",
    "summary": "Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio",
    "url": "https://www.marketbeat.com/stock-ideas/3-smart-defensive-stocks-for-an-uneasy-market/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "ad0a970b-5a4c-3a64-af8d-1ea4e1cbbbd1",
      "content": {
        "id": "ad0a970b-5a4c-3a64-af8d-1ea4e1cbbbd1",
        "contentType": "STORY",
        "title": "3 Smart Defensive Stocks for an Uneasy Market",
        "description": "",
        "summary": "Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio",
        "pubDate": "2025-11-18T15:07:00Z",
        "displayTime": "2025-11-18T15:07:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/102b5d57bb0b3282684fc015d092a0b7",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NfXf_.mmtjEpjNNOOAIsnw--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/102b5d57bb0b3282684fc015d092a0b7.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qJTBt5bfEGRLy4K.jUPU4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/102b5d57bb0b3282684fc015d092a0b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/stock-ideas/3-smart-defensive-stocks-for-an-uneasy-market/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-smart-defensive-stocks-uneasy-150700656.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JPM"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "DIA"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]